Stock Scorecard



Stock Summary for Becton Dickinson & Company (BDX) - $202.75 as of 1/12/2026 7:08:41 PM EST

Total Score

9 out of 30

Safety Score

45 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for BDX

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for BDX

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for BDX

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for BDX

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for BDX (45 out of 100)

Stock Price Rating (Max of 10) 10
Historical Stock Price Rating (Max of 10) 10
Stock Price Trend (Max of 10) 2
Book Value (Max of 10) 9
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 3
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 4
Operating Margin (Max of 10) 4
Trading Volume (Max of 10) 9
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) -10

Latest News for for BDX

Waters Corp Announces Presentation at J.P. Morgan Healthcare Conference 1/12/2026 10:27:00 PM
Severe Sepsis Infection Leads to Vortex Port Catheter Wrongful Death Lawsuit 1/12/2026 4:29:00 PM
BioMed Realty and TransMedics Announce 498,000-Square-Foot Lease at Assembly Innovation Park 1/12/2026 1:57:00 PM
Is Enovis (ENOV) Elevating Execution Risk Management With Its New Chief Administrative Officer? 1/10/2026 8:12:00 PM
The Truth About Baxter International Inc.: Why Wall Street Suddenly Can’t Ignore It 1/10/2026 5:59:00 PM
5 trends defining the next wave of life sciences M&A 1/9/2026 4:11:00 PM
Is BD (BDX) Quietly Recasting Its Surgical Innovation Story With Expanded Phasix Mesh Use in Europe? 1/8/2026 11:08:00 PM
Is BD (BDX) Quietly Recasting Its Surgical Innovation Story With Expanded Phasix Mesh Use in Europe? 1/8/2026 10:54:00 PM
What Can Investors Anticipate in Becton, Dickinson and Company's Upcoming Quarterly Earnings Release 1/8/2026 9:09:00 PM
What Can Investors Anticipate in Becton, Dickinson and Company's Upcoming Quarterly Earnings Release 1/8/2026 9:08:00 PM

Financial Details for BDX

Company Overview

Ticker BDX
Company Name Becton Dickinson & Company
Country N/A
Description Becton, Dickinson and Company (BDX) is a premier American multinational medical technology firm, focused on the development and manufacture of vital medical devices, instrument systems, and reagents that enhance healthcare outcomes worldwide. With a comprehensive product portfolio addressing diverse diagnostic and therapeutic needs, BDX maintains a strong presence in the global healthcare market while offering analytical and consulting services to optimize operational efficiency. The company's unwavering commitment to innovation, demonstrated through substantial investments in research and development, positions BDX to leverage emerging trends in the medical technology sector, reinforcing its leadership role in delivering next-generation healthcare solutions.
Sector Name HEALTHCARE
Industry Name MEDICAL INSTRUMENTS & SUPPLIES
Most Recent Quarter 9/30/2025
Next Earnings Date N/A

Stock Price History

Last Day Price 202.75
Price 4 Years Ago 241.14
Last Day Price Updated 1/12/2026 7:08:41 PM EST
Last Day Volume 1,321,253
Average Daily Volume 1,826,570
52-Week High 246.65
52-Week Low 160.60
Last Price to 52 Week Low 26.25%

Valuation Measures

Trailing PE N/A
Industry PE 647.99
Sector PE 123.98
5-Year Average PE 13.65
Free Cash Flow Ratio 90.11
Industry Free Cash Flow Ratio 32.74
Sector Free Cash Flow Ratio 29.04
Current Ratio Most Recent Quarter 1.11
Total Cash Per Share 2.25
Book Value Per Share Most Recent Quarter 88.96
Price to Book Ratio 2.28
Industry Price to Book Ratio 3.44
Sector Price to Book Ratio 24.69
Price to Sales Ratio Twelve Trailing Months 2.68
Industry Price to Sales Ratio Twelve Trailing Months 79.25
Sector Price to Sales Ratio Twelve Trailing Months 19.33
Analyst Buy Ratings 3
Analyst Strong Buy Ratings 2

Share Statistics

Total Shares Outstanding 284,908,000
Market Capitalization 57,765,097,000
Institutional Ownership N/A

Dividends

Ex-Dividend Date 12/8/2025
Previous Dividend Amount 1.0400
Current Dividend Amount 1.0500
Total Years Dividend Increasing Dividend Aristocrat - Increasing for 41 Years
Trailing Annual Dividend Rate 4.17
Trailing Annual Dividend Yield 2.06%
Forward Annual Dividend Rate 4.20
Forward Annual Dividend Yield 2.07%
5-Year Dividend Payments Count 20
3-Year Average Dividend Yield 1.82%
5-Year Average Dividend Yield 1.68%
1-Year Dividend Growth Rate Percentage 7.20%
3-Year Dividend Growth Rate Percentage 6.45%
5-Year Dividend Growth Rate Percentage 5.55%
All-Time Dividend Growth Rate Percentage 10.49%
Dividend Payout Ratio 71.53%

Income Statement

Quarterly Earnings Growth YOY 25.20%
Annual Earnings Growth -1.58%
Reported EPS 12 Trailing Months 5.83
Reported EPS Past Year 0.00
Reported EPS Prior Year 14.42
Net Income Twelve Trailing Months 1,597,000,000
Net Income Past Year 1,678,000,000
Net Income Prior Year 1,705,000,000
Quarterly Revenue Growth YOY 8.30%
5-Year Revenue Growth 6.32%
Operating Margin Twelve Trailing Months 17.90%

Balance Sheet

Total Cash Most Recent Quarter 641,000,000
Total Cash Past Year 851,000,000
Total Cash Prior Year 1,717,000,000
Net Cash Position Most Recent Quarter -16,980,000,000
Net Cash Position Past Year -16,770,000,000
Long Term Debt Past Year 17,621,000,000
Long Term Debt Prior Year 17,940,000,000
Total Debt Most Recent Quarter 17,621,000,000
Equity to Debt Ratio Past Year 0.59
Equity to Debt Ratio Most Recent Quarter 0.59
Total Stockholder Equity Past Year 25,390,000,000
Total Stockholder Equity Prior Year 25,889,000,000
Total Stockholder Equity Most Recent Quarter 25,390,000,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months 4,295,000,000
Free Cash Flow Per Share Twelve Trailing Months 15.08
Free Cash Flow Past Year 2,670,000,000
Free Cash Flow Prior Year 3,073,000,000

Options

Put/Call Ratio 0.12
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 2.21
MACD Signal 1.86
20-Day Bollinger Lower Band 176.64
20-Day Bollinger Middle Band 190.23
20-Day Bollinger Upper Band 203.82
Beta 0.26
RSI 60.54
50-Day SMA 192.96
150-Day SMA 220.99
200-Day SMA 224.20

System

Modified 1/12/2026 6:27:30 PM EST